FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY - Study will enrol 200 adult patients with limb trauma who are rescued by helicopter - Efficacy, tolerability and practicality of use of the inhaled analgesic in hostile mountain environments to be investigated Cambridge, England (ots/PRNewswire) - The Mundipharma network ...
Basel, Switzerland (ots/PRNewswire) - Mundipharma EDO GmbH, part of the Mundipharma global network of independent associated companies, today announced that the first patient has been enrolled in the expansion stage of a Phase I/II clinical trial of tinostamustine in patients with relapsed/refractory (R/R) ...
Cambridge, England (ots/PRNewswire) - - flutiform k-haler is now available in Europe as an asthma treatment for adults and adolescents (aged 12 years and older)[1] - Research indicates that many patients make errors with their inhalers and this is associated with poor asthma control and increased exacerbations[2] - ...
Cambridge, England (ots/PRNewswire) - - First presentation of largest ever real-world flutiform® study at European Respiratory Society International Congress involving over 2,500 patients - Proportion of patients with well-controlled asthma more than doubled 12 months after switching to flutiform pMDI New ...
Cambridge, England (ots/PRNewswire) - - flutiform k-haler achieved high levels of lung deposition of over 44% of delivered dose - Plume force of flutiform k-haler was compared with fluticasone propionate/salmeterol xinafoate delivered via the Seretide® Evohaler® pMDI and Sirdupla® pMDI devices - Pharmacokinetic ...
Cambridge, England (ots/PRNewswire) - Mundipharma announced today that they have submitted a file to the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA) seeking a licence for its new product flutiform® K-Haler®. The indication sought is for the treatment of asthma in adults and adolescents where the use of a combination product ...
Florence, Italy (ots/PRNewswire) - First ever Europe-wide study reveals that even when undergraduate medical students take a compulsory course on pain, they still only receive on average 12 hours' training There is an alarming lack of dedicated teaching on pain in undergraduate medical schools in Europe, according ...
Cambridge, England (ots/PRNewswire) - Mundipharma Research Limited (Mundipharma) announced today a major milestone in the development programme of flutiform(R)(fluticasone propionate / formoterol fumarate) for the treatment of Chronic Obstructive Pulmonary Disease (COPD) with the commencement of a key clinical trial. COPD is a life-threatening lung disease that interferes with normal breathing, estimated to affect at least 64 million people worldwide[1]. The first patient in ...
Cambridge, England (ots/PRNewswire) - NOT INTENDED FOR MEDIA IN THE NETHERLANDS -Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; ...
Cambridge, England (ots/PRNewswire) - - Total of 43 bendamustine abstracts to be presented at ASH, including five oral presentations - New data supports use of bendamustine-rituximab (B-R) regimen in indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL) 43 abstracts, announcing the results of studies ...
Cambridge, England (ots/PRNewswire) - First national approvals expected by the end of 2012 Mundipharma today announced the positive European Commission (EC) decision for flutiform(R) (fluticasone propionate/formoterol fumarate), a new combination therapy for the maintenance treatment of asthma, in Europe. This ...
Cambridge, England (ots/PRNewswire) - New research demonstrates oxycodone/naloxone prolonged-release tablets superiority compared with oxycodone prolonged-release tablets[1] Treatment with Targin(R)(oxycodone/naloxone) prolonged-release tablets provides superior bowel function without compromising analgesic efficacy ...
Cambridge, England, March 19, 2010 (ots/PRNewswire) - Mundipharma announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending that marketing authorisations can be granted in Germany and the following Member States of the EU: Austria, Belgium, Denmark, Finland, ...
Cambridge, England (ots/PRNewswire) - - Blood Marrow Normalised in 31% (Versus 2%) of Patients, With Manageable Side-Effects Nearly a third (31%) of all bendamustine-treated patients saw all clinical evidence of their advanced chronic lymphocytic leukaemia (CLL) disappear when used as a first-line ...
Cambridge, England (ots/PRNewswire) - - New Approach in the Development of Opioid-Based Pain Management Therapy Improves Bowel Function The oral prolonged-release (PR) oxycodone / naloxone combination tablet reduces opioid-induced bowel dysfunction in patients with chronic severe pain compared to ...